Table 3.
8 + 0 to 10 + 6 weeks (n = 16) | 11 + 0 to 13 + 6 weeks (n = 14) | ||||||
---|---|---|---|---|---|---|---|
DR (% (95% CI)) at: | DR (% (95% CI)) at: | ||||||
Method of screening | AUC (95% CI) | 5% FPR | 10% FPR | AUC (95% CI) | 5% FPR | 10% FPR | P * |
A‐priori risk plus: | |||||||
MAP | 0.757 (0.647–0.866) | 25.0 (6.3–43.8) | 37.5 (18.8–68.8) | 0.736 (0.590–0.883) | 28.6 (7.1–50.0) | 35.7 (7.1–64.3) | 0.841 |
UtA‐PI | 0.724 (0.564–0.884) | 43.8 (18.8–68.8) | 50.0 (25.0–75.0) | 0.688 (0.541–0.835) | 28.6 (7.1–50.0) | 35.7 (14.3–64.3) | 0.738 |
PAPP‐A | 0.678 (0.520–0.835) | 25.0 (6.3–50.0) | 43.8 (18.8–68.8) | 0.748 (0.621–0.875) | 14.3 (0–35.7) | 35.7 (7.1–64.3) | 0.511 |
PlGF | 0.719 (0.593–0.846) | 25.0 (6.3–43.8) | 25.0 (6.3–43.8) | 0.712 (0.569–0.855) | 35.7 (14.3–64.3) | 35.7 (14.3–64.3) | 0.948 |
PlGF + UtA‐PI | 0.746 (0.589–0.903) | 37.5 (12.5–62.5) | 43.8 (18.8–68.8) | 0.719 (0.571–0.866) | 42.9 (14.3–71.4) | 42.9 (14.3–71.4) | 0.798 |
MAP + PlGF | 0.802 (0.717–0.888) | 25.0 (6.3–50.0) | 31.3 (12.5–56.3) | 0.799 (0.654–0.944) | 28.6 (7.1–57.1) | 57.1 (28.6–85.7) | 0.976 |
MAP + UtA‐PI | 0.798 (0.701–0.894) | 31.3 (12.5–56.3) | 31.3 (12.5–56.3) | 0.765 (0.604–0.926) | 42.9 (14.3–71.4) | 50.0 (21.4–78.6) | 0.743 |
PAPP‐A + PlGF | 0.723 (0.595–0.851) | 25.0 (6.3–43.8) | 25.0 (6.3–50.0) | 0.777 (0.648–0.906) | 35.7 (14.3–64.3) | 42.9 (21.4–71.4) | 0.636 |
MAP + PAPP‐A | 0.780 (0.678–0.883) | 37.5 (18.8–62.5) | 43.8 (18.8–68.8) | 0.765 (0.620–0.910) | 28.6 (7.1–50.0) | 42.9 (14.3–71.4) | 0.883 |
UtA‐PI + PAPP‐A | 0.744 (0.585–0.902) | 43.8 (18.8–68.8) | 50.0 (25.0–75.0) | 0.709 (0.565–0.853) | 21.4 (7.1–50.0) | 35.7 (14.3–64.3) | 0.742 |
MAP + UtA‐PI + PAPP‐A | 0.815 (0.720–0.909) | 31.3 (12.5–56.3) | 37.5 (12.5–62.5) | 0.779 (0.619–0.938) | 42.9 (21.4–71.4) | 50.0 (28.4–78.6) | 0.714 |
MAP + UtA‐PI + PlGF | 0.804 (0.687–0.920) | 31.3 (12.5–56.3) | 37.5 (12.5–62.5) | 0.793 (0.636–0.950) | 42.9 (21.4–71.4) | 50.0 (21.4–78.6) | 0.911 |
MAP + PAPP‐A + PlGF | 0.803 (0.721–0.885) | 31.3 (12.5–62.5) | 37.5 (12.5–62.5) | 0.801 (0.660–0.941) | 28.6 (7.1–57.1) | 50.0 (21.4–78.6) | 0.984 |
UtA‐PI + PlGF + PAPP‐A | 0.749 (0.592–0.906) | 37.5 (12.5–62.5) | 43.8 (18.8–68.8) | 0.722 (0.575–0.969) | 42.9 (14.3–71.4) | 42.9 (14.3–71.4) | 0.798 |
MAP + UtA‐PI + PlGF + PAPP‐A | 0.772 (0.639–0.904) | 31.3 (12.5–56.3) | 50.0 (25.0–75.0) | 0.795 (0.640–0.950) | 35.7 (14.3–64.3) | 64.3 (35.7–85.7) | 0.803 |
Comparison between AUCs was by two‐tailed P‐value.
FPR, false‐positive rate; MAP, mean arterial pressure; UtA‐PI, uterine artery pulsatility index.